Coronavirus: further extension of the measures taken by the FAMHP to avoid medicinal product shortages

date: 28/01/2021

On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. These measures have again been extended by one month.

Stocks of medicinal products used to treat COVID-19 patients have been closely monitored by the FAMHP since the onset of the COVID-19 crisis.

As of 1 April 2020, the FAMHP has drawn up a list of medicinal products and raw materials used in the treatment of COVID-19 for which emergency measures have been taken. These measures have then been refined and extended. Since mid-June 2020, these are mainly measures relating to quotas for wholesalers.

These measures are needed in light of the evolution of the pandemic. Medicines with adrenaline as only active ingredient are now also included in the list of medicines of the decision. Adrenaline is an important medicine used in COVID-19 vaccination. The medicine is necessary to treat a known adverse reaction, anaphylactic shock.

The new decision extends the measures up to and including 28 February 2021.

Thanks to these measures and their extension, solutions and alternatives for all the medicinal products necessary for the treatment of COVID-19 patients in Belgium currently exist and will exist in the near future.

More information

Last updated on 26/02/2021